SEC Form 4 · accession 0000899243-18-000952
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Radovich
Officer — See Remarks
Period of report
Jan 10, 2018
Accepted (ET)
Jan 11, 2018 · 9:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 10, 2018 | M | 15,000 | $1.61 | A | 17,684 | D | |
| Common Stock | Jan 10, 2018 | S | 15,000 | $50.00 | D | 2,684 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $1.61 | Jan 10, 2018 | M | 15,000 | D | — | Jan 20, 2025 | Common Stock | 15,000 | 65,000 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F225% of the shares subject to this option vested and became exercisable on November 17, 2015, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter.
Remarks
Senior Vice President, Operations